Assertio Holdings (ASRT) Depreciation & Amortization (CF) (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Depreciation & Amortization (CF) came in at $5.8 million in Q1 2026, down 36.99% year-on-year from $9.3 million in Q1 2025, and little changed quarter-over-quarter from $5.8 million in Q4 2025.
Assertio Holdings (ASRT) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $5.8 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $5.8 million, down 36.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.6 million (down 9.61% YoY), and the FY2025 annual result was $30.0 million, up 16.17% from the prior year.
- Depreciation & Amortization (CF) came in at $5.8 million for Q1 2026 at Assertio Holdings, roughly flat from $5.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.4 million in Q3 2023 to a low of $4.9 million in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $6.7 million (2024), against an average of $7.3 million.
- Across the five-year window, Depreciation & Amortization (CF) slumped 41.31% in 2023 and surged 62.73% in 2025, its largest moves.
- Assertio Holdings' Depreciation & Amortization (CF) stood at $8.4 million in 2022, then sank by 41.31% to $4.9 million in 2023, then jumped by 36.74% to $6.7 million in 2024, then declined by 12.99% to $5.8 million in 2025, then advanced by 0.02% to $5.8 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 5.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.84 Mn |
| Mar 31, 2026 | 5.84 Mn |
| Dec 31, 2025 | 5.84 Mn |
| Dec 31, 2025 | 5.84 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.63 Mn |
| Jun 30, 2025 | 9.27 Mn |
| Jun 30, 2025 | 9.27 Mn |
| Mar 31, 2025 | 9.27 Mn |
| Mar 31, 2025 | 9.27 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 6.71 Mn |
| Sep 30, 2024 | 6.71 Mn |
| Jun 30, 2024 | 6.71 Mn |
| Jun 30, 2024 | 6.71 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Dec 31, 2023 | 4.91 Mn |